Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create a world-class ophthalmology player, while advancing the former’s primary focus on blindness and regeneration. Based in New Jersey, Iveric Bio is a biopharma company engaged in discovering and developing novel […]